Minoxidil was never intended to grow hair. Developed in the 1960s as an antihypertensive agent, its capacity to stimulate hair growth was discovered by accident — and that serendipitous observation has since made it the most widely used pharmacological treatment for hair loss in the world.
A Discovery Made by Accident
Minoxidil was first synthesised in the late 1950s during a drug discovery programme at the Upjohn Company, initially investigated as a treatment for gastric ulcers — an indication for which it proved ineffective. Its potent vasodilatory properties, however, redirected attention toward cardiovascular medicine, and in 1979 the FDA approved oral minoxidil under the brand name Loniten for severe, refractory hypertension.1
What followed was one of medicine's more fortuitous observations. Patients enrolled in early antihypertensive trials began reporting an unexpected and striking adverse effect: excessive hair growth — hypertrichosis — across the scalp and body. Rather than dismissing the finding, researchers recognised its clinical potential and began exploring topical formulations that might capture the hair-stimulatory effect while avoiding systemic hypotension.2
Originally investigated for gastric ulcers. Proved ineffective, but potent vasodilatory effects noted in animal studies redirected research toward cardiovascular use.
The molecule was formally named and pursued as a systemic arteriolar vasodilator for blood pressure management.
Approved as Loniten for severe hypertension unresponsive to other therapies. Hypertrichosis noted as a striking side effect in clinical trial participants.
Topical 2% minoxidil approved for male androgenetic alopecia. One of the first pharmacotherapies approved specifically for hair loss.
Approval extended to women with pattern hair loss, cementing minoxidil as the leading first-line pharmacological treatment for androgenic alopecia in both sexes.3
Off-label low-dose oral minoxidil (0.5–5 mg daily) emerges as a growing alternative to topical therapy, with randomised trial evidence supporting comparable or superior efficacy.4
How Minoxidil Works
Despite decades of clinical use, the precise molecular mechanism of minoxidil's hair-stimulating effect is not fully elucidated. What is established is that multiple complementary pathways are involved, and no single mechanism fully explains the observed clinical response.5
Prodrug Activation
Minoxidil is a prodrug. It requires conversion to minoxidil sulfate by sulfotransferase enzymes (primarily SULT1A1) in the hair follicle's outer root sheath to become biologically active.5
Hair Cycle Modulation
Minoxidil sulfate accelerates the transition from telogen (resting) to anagen (growth) phase, prolongs the anagen phase, and counteracts the follicular miniaturisation characteristic of androgenetic alopecia.6
Vascular & Signalling Effects
Original vasodilatory properties enhance perifollicular microvascular blood flow. Minoxidil also influences VEGF expression, prostaglandin synthesis, and Wnt/β-catenin signalling pathways linked to follicular proliferation.7
Minoxidil is a prodrug — it does nothing until activated locally within the follicle itself. This single enzymatic step explains much of the variation in treatment response between individuals.
Topical vs. Oral: A Practical Comparison
Minoxidil is available in two principal formulations for hair loss, each with distinct pharmacokinetic profiles, regulatory status, and clinical evidence bases. The choice between them is increasingly informed by individual patient factors, including lifestyle, genetics, and tolerability.
A 2024 randomised trial published in JAMA Dermatology comparing oral and topical formulations in male androgenetic alopecia found similar improvements in hair density and patient satisfaction between groups, with some evidence favouring oral minoxidil for photographic improvement — though the authors noted that larger studies are required to confirm superiority.4
Onset of Effect: What Patients Should Expect
Genetics of Treatment Response
One of the most clinically useful — and underappreciated — aspects of minoxidil pharmacology is the genetic variation in treatment response. Because topical minoxidil depends on local conversion to its active metabolite by SULT1A1 within the hair follicle, individuals with lower follicular sulfotransferase activity show significantly reduced response to topical application.8 This explains the clinical observation that some patients achieve dramatic regrowth while others see little improvement despite consistent use.
High SULT1A1 Activity
Individuals with high follicular sulfotransferase activity convert minoxidil to its active sulfate form efficiently. These patients are the best topical responders and typically see significant hair regrowth within the first six months of consistent use.8
Low SULT1A1 Activity
Genetically lower enzyme activity impairs local conversion of topical minoxidil, producing a suboptimal or absent clinical response. These patients may be better candidates for oral minoxidil, which undergoes systemic and hepatic activation.9
Oral as a Bypass
Oral minoxidil, absorbed systemically and activated hepatically, is less dependent on follicular enzyme levels. Emerging evidence suggests it may demonstrate broader efficacy across genetic subgroups who respond poorly to topical therapy.4,9
Dosing Reference
| Formulation | Typical Dose | Application / Notes |
|---|---|---|
| Topical 2% solution | 1 mL twice daily | FDA-approved; OTC; standard first-line for women |
| Topical 5% solution | 1 mL once or twice daily | Greater efficacy than 2%; preferred for men |
| Topical 5% foam | Half capful once daily | Less scalp irritation; suitable for fine hair |
| Oral (off-label) | 0.5–2.5 mg daily (women) / 1.25–5 mg daily (men) | Requires medical prescription and monitoring4 |
| Compounded topical (8–10%) | Variable | Not FDA-approved; limited evidence; specialist use only |
Safety Considerations
Topical minoxidil has an excellent safety record at standard concentrations, with systemic absorption of approximately 1–1.4% of the applied dose.1 Contact dermatitis, scalp irritation, and localised hypertrichosis at sites of inadvertent application are the most commonly reported adverse effects with topical use.
Oral minoxidil carries a higher potential for systemic effects at hair loss doses — most notably fluid retention, peripheral oedema, and unwanted body hair growth (hypertrichosis).10 These are generally mild and dose-dependent at the low doses used for alopecia. Oral minoxidil should not be initiated without a thorough cardiovascular history and is contraindicated in patients with significant cardiac, hepatic, or renal disease. In Australia, it requires a prescription and should be managed under medical supervision.
An initial telogen effluvium — a temporary increase in hair shedding in the first four to eight weeks of treatment — is frequently observed and often alarms patients. This is a normal and transient physiological response to follicular cycling, not evidence of treatment failure, and resolves spontaneously as the anagen phase is established.6
Conclusion
Minoxidil's journey from an antihypertensive drug to the world's most widely used hair loss treatment is one of medicine's more compelling stories of pharmacological serendipity. Its mechanisms remain incompletely understood, but its clinical utility is well established across both topical and oral formulations. The emerging understanding of genetic variability in SULT1A1 activity is beginning to offer a framework for personalising treatment selection — moving beyond a one-size-fits-all approach toward a more informed clinical decision for each individual patient.
References
- Campese VM. Minoxidil: a review of its pharmacological properties and therapeutic use. Drugs. 1981;22(4):257–278.
- Headington JT, Novak E. Clinical and histologic studies of male pattern baldness treated with topical minoxidil. Curr Ther Res. 1984;36(4):1–6.
- Cortez AP, Weffort-Santos AM, Mulinari-Brenner FA. Male androgenetic alopecia. An Bras Dermatol. 2024;99(1):1–12.
- Penha MA, Shapiro J, Lartey RT, et al. Oral minoxidil versus topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024;160(2):156–163.
- Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. J Dermatolog Treat. 2022;33(4):1896–1906.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777–2786.
- Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138(3):407–411.
- Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatol Ther. 2014;27(6):171–173.
- Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: tolerability & the five α's of oral minoxidil. Dermatol Ther. 2018;31(6):e12707.
- Jimenez-Cauhe J, Ortega-Quijano D, Carretero-Barrio I, et al. Erythema multiforme secondary to low-dose oral minoxidil treatment for androgenetic alopecia. J Am Acad Dermatol. 2020;83(2):e143–e144.